UNSPSC 51313704: Ketotifen

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X49220T18G, chemically known as 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one but generally known as ketotifen, which bears US NIH Compound Identifier 3827. European Medicines Agency schedules Ketotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08377MIG.

UNSPSC 51313704 Ketotifen is a Commodity code designating a specific pharmaceutical product, but the recent state and local contract opportunities tagged under it reveal a broader procurement pattern: state and local health agencies are acquiring multiple categories of pharmaceuticals and related health products — including naloxone, generic multi-source medications, and over-the-counter products — through competitive solicitations. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state, local, and participating out-of-state jurisdictions including Oregon). These buyers source through a mix of direct procurement and wholesaler-mediated arrangements, with contracts typically spanning two years and including options for renewal or extension.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to Seminole County Community Health Building in Sanford, response due July 26, 2026 (note: the source lists a conflicting prior date of July 26, 2023, but the posting date of June 30, 2026 suggests 2026 is current). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory information-gathering phase designed to inform future formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three solicitations require vendors to meet cGMP, Drug Supply Chain Security Act compliance, specific insurance thresholds, and E-Verify confirmation; none explicitly designate set-asides for disadvantaged enterprises. The code shows limited recent activity and does not consistently represent single-product procurement — the opportunities reflect broader pharmaceutical supply contracts in which ketotifen may be one line item among many.